Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Inovio Pharmaceuticals Jumped Higher Today

By Brian Orelli, PhD - Feb 10, 2020 at 12:56PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is starting a new clinical trial, but that may not be the only thing boosting the biotech's shares.

What happened

Shares of Inovio Pharmaceuticals (INO -5.03%) are up 14.8% at 12:16 p.m. EST after the Food and Drug Administration accepted its application to start a phase 1/2 clinical trial testing INO-3107 in a clinical trial of patients with recurrent respiratory papillomatosis.

So what

Recurrent respiratory papillomatosis is caused by infection with the human papillomavirus (HPV), which forms noncancerous tumors that grow large enough that they block the patient's airway and have to be surgically removed. Unfortunately the surgery usually doesn't remove all of the tumor, which then regrows, requiring that surgery be repeated, often multiple times a year. The disease can also progress to full-blown cancer in some cases.

INO-3107 is essentially a vaccine that generates an immune response to two strains of HPV that cause recurrent respiratory papillomatosis. The biotech ran a pilot study of an earlier version called INO-3106 that targeted only one strain of HPV. Two patients in the study, who had required approximately two surgeries per year, were able to delay surgery by 584 days and 915 days, respectively, after taking INO-3106.

Doctor listening to a patient's chest with a stethoscope

Image source: Getty Images.

Now what

Moving a drug into the clinic is certainly good news, but it's only the start of the marathon that is drug development and doesn't justify today's double-digit move.

Inovio Pharmaceuticals is probably rising today also because there doesn't appear to be an end in sight for the 2019-nCoV coronavirus outbreak. A couple of weeks ago, the biotech announced that it had received a grant from the Coalition for Epidemic Preparedness Innovations to develop INO-4800, a vaccine agaisnt 2019-nCoV. Unfortunately it isn't clear how long it may take for Inovio to get INO-4800 into the clinic, so investors should be careful ascribing too much value to the coronavirus program until a timeline is more apparent.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$1.89 (-5.03%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.